Special Issue "Drug Delivery to Brain Tumors"
Deadline for manuscript submissions: closed (30 November 2020).
Interests: bioimmunotherapy; tumor micro environment; CNS drug delivery
Interests: glioblastoma; glioma; brain metastasis; neurosurgical oncology; convection enhanced delivery; innovation
Clinical outcomes following treatment of primary malignant brain tumors are far from satisfactory. One of the main obstacles to the development of effective therapies is failure to achieve therapeutically relevant concentrations in the CNS due to the presence of blood–brain and/or blood–brain–tumor barriers. Some of the approaches explored to address this challenge include blood–brain barrier disruption and drug modifications to enhance CNS permeability; unfortunately, neither approach has proven successful. Another approach is to deliver therapeutics locoregionally, directly into the tumor mass and surrounding tumor-infiltrated brain parenchyma. The most widely used method for direct brain delivery is convection-enhanced delivery (CED), whereby specially designed catheters are introduced into target tissue and the infusate is delivered slowly over a prolonged period of time. CED enables delivery of conventional, nano-, bio-, gene, and even cellular therapies. This Special Issue provides a highlight of the most recent progress made to improve the efficacy of therapeutics delivered directly to brain tumors.
Prof. Dr. Waldemar Debinski
Prof. Dr. Michael Vogelbaum
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- brain tumors
- blood–brain barrier (BBB)
- convection-enhanced delivery (CED)
- electric fields
- high-intensity focused ultrasound (HIFU)
- MRI monitoring
- intraventricular and intrathecal delivery
- drug formulation
- preclinical models